The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera; PsiOxus Therapeutics
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Geneos; Lilly; Natera; Parker Institute for Cancer Immunotherapy; PsiOxus Therapeutics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Max Miller Wattenberg
Consulting or Advisory Role - NanOlogy
Research Funding - HiberCell; Lilly
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Michael Jay Yellin
Employment - Celldex
Stock and Other Ownership Interests - Celldex
 
Tibor Keler
Employment - Celldex
Leadership - Celldex
Stock and Other Ownership Interests - Celldex
 
Michele Anne Gargano
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell; Immuno Research
 
Nick Niles
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
 
Jeremy Drees
Employment - HiberCell
Stock and Other Ownership Interests - HiberCell
 
Nandita Bose
Employment - HiberCell
Leadership - HiberCell
Stock and Other Ownership Interests - HiberCell; Immuno Research
Patents, Royalties, Other Intellectual Property - HiberCell
 
Jose Luis Iglesias
Consulting or Advisory Role - Amplia Therapeutics; Aucentra Therapeutics; Carina Biotech; Engine Biosciences; Epsilogen; HIberCell; Immunovaccine; Panavance Therapeutics
 
Gregory Lawrence Beatty
Stock and Other Ownership Interests - Johnson & Johnson
Honoraria - Incyte; Janssen
Consulting or Advisory Role - Adicet Bio; Aduro Biotech; AstraZeneca; BiolineRx; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Cour Pharmaceuticals; Genmab; Hibercell; Hotspot Therapeutics; Incyte; Janssen; Legend Biotech; Merck; Molecular Partners; Monopteros Therapeutics; NanoGhost; Pancreatic Cancer Action Network; Seagen; Shattuck Labs; Verastem
Research Funding - Alligator Bioscience; Arcus Biosciences; Biothera; Bristol-Myers Squibb; Genmab; Gilead Sciences; Halozyme; HiberCell; Incyte; Janssen; Monopteros Therapeutics; Newlink Genetics; Verastem
Patents, Royalties, Other Intellectual Property - Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Novartis.; Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Tmnuity.